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ABSTRACT
Background: The conventional devices available for the 
percutaneous occlusion of a patent ductus arteriosus (PDA) 
may have limitations, especially in small children and adults 
with a large ductus arteriosus. The Amplatzer® Vascular 
Plug II (AVP II) device has been used in these scenarios 
with promising results. This study aims to report an early 
experience with the AVP II device at three reference centres. 
Methods: This was a prospective study with retrospectively 
collected data from patients who had undergone PDA occlu-
sion with the AVP II since 2011. The devices were implanted 
using the anterograde approach under general anaesthesia, 
except for in one patient. Technical aspects, immediate 
occlusion, and complication rates were assessed. Results: 
Forty patients (67.5% females) with a median age of 56.7 
months (6 months to 654.7 months) and a median weight 
of 17.3 kg (5 kg to 93 kg) were included. Of these, 36 had 
a type A PDA, three had a type E PDA, and one had a type 
C PDA. The mean diameters of the ductus and of the device 
were 3.7  ±  1.5  mm and 9.4  ±  3.6  mm, respectively. In 3 
patients, the initial device had to be replaced by another 
device of a different size. In one patient, an unsuccessful 
attempt led to the use of two implant devices. This patient 
was later referred for surgical repair. In five patients, a 
mild protrusion of the disc towards the aorta was observed, 
but the protrusion did not cause a significant pressure 
gradient. Residual flow was observed in two patients. There 
were no significant complications. Conclusions: The AVP II 
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RESUMO
Oclusão Percutânea do Canal Arterial com a  
Prótese Amplatzer® Vascular Plug II:  
Experiência Inicial em Três Centros de Referência
Introdução: As próteses convencionais disponíveis para o fe-
chamento percutâneo da persistência do canal arterial (PCA) 
podem apresentar algumas limitações a seu uso, principalmente 
em crianças pequenas e em adultos com canais de maior diâ-
metro. A prótese Amplatzer® Vascular Plug II (AVP II) tem sido 
utilizada nesses casos com resultados animadores. Objetivamos 
apresentar a experiência inicial com AVP II em três centros de 
referência. Métodos: Estudo prospectivo, com coleta de dados 
retrospectiva, dos pacientes submetidos a fechamento de PCA 
com AVP II desde 2011. Os dispositivos foram implantados sob 
anestesia geral por via anterógrada, exceto em um paciente. 
Foram avaliados aspectos técnicos, taxa de oclusão imediata 
e complicações. Resultados: Foram selecionados 40 pacientes 
(67,5% do sexo feminino) com mediana de idade de 56,7 
meses (6 meses a 654,7 meses) e mediana de peso de 17,3 kg 
(5 kg a 93 kg). Desses pacientes, 36 tinham PCA do tipo A, 
3 do tipo E e 1 do tipo C. Os diâmetros médios do canal e da 
prótese foram de 3,7 ± 1,5 mm e de 9,4 ± 3,6 mm, respec-
tivamente. Em 3 pacientes foi necessária a troca do dispositivo 
inicial por outro de diferente tamanho. Em uma paciente foi 
realizada tentativa de implante com 2 dispositivos, sem sucesso, 
a qual foi posteriormente encaminhada para correção cirúrgica. 
Em 5 pacientes foi observada discreta protrusão do disco para 
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device is a safe and effective alternative for PDA treatment, 
especially in patients with limitations to the conventional 
occlusion procedure.
 
 
DESCRIPTORS: Ductus arteriosus. Prostheses and implants. 
Heart defects, congenital. Heart catheterisation.
P atent ductus arteriosus (PDA) is one of the most common congenital cardiac lesions and accounts for up to 7% of all congenital heart diseases.1,2 
Treatment is indicated in the first year of life when 
there is heart failure or later, when there are negative 
hemodynamic consequences, including increased left 
ventricular dimensions on echocardiography.2 The timely 
closure of a PDA prevents the onset of complications 
such as heart failure, pulmonary arterial hypertension, 
arrhythmias, and possibly infectious endarteritis.1,2
The percutaneous treatment of PDAs with last-
generation intra-cardiac prostheses has been safely 
and effectively performed in several age groups, with 
the exception of neonates and young infants weighing 
<  4 to 5  kg.3
Several devices are used for closing a PDA; coils 
and plugs are the most common devices. The latter 
are prostheses designed exclusively for closing a PDA 
and consist of a body and a retention disc, which is 
positioned in the aortic side of the defect.3,4 However, 
in some anatomic variations5 (large-calibre tubular 
ductus, type A ductus with shallow aortic ampulla 
and small diameter, and angulated ductus), especially 
in low-weight patients, the distal disc can protrude to 
the aortic side and generate a pressure gradient in the 
aorta. The protrusion into the left pulmonary artery can 
also be occasionally observed in patients weighing < 8 
to 10  kg. Moreover, the plug-type prosthesis, usually 
indicated for a ductus with a minimum diameter > 2.5 
to 3 mm, is not provided by the Brazilian Unified Health 
System (Sistema Único de Saúde – SUS) in Brazil, 
which limits the percutaneous treatment of PDAs in 
significant parts of the population of patients with this 
condition, including adults who typically have a larger 
diameter ductus and a wide and deep aortic ampulla. 
To overcome some of these limitations, the Amplatzer® 
Vascular Plug II device (AVP II, St. Jude Medical – St 
Paul, USA), originally designed for vessel occlusion, has 
been used for the percutaneous treatment of PDA with 
promising initial results.6-8 However, there have been 
few reports in the literature on studies of patients in 
whom this type of prosthesis was used for PDA closure.
The aim of this study was to present the experien ce 
of three hemodynamic services specialising in the treat-
ment of congenital heart disease with the use of the AVP 
a aorta sem ocasionar gradiente pressórico significativo. Houve 
fluxo residual em 2 pacientes. Não ocorreram complicações 
significativas. Conclusões: O dispositivo AVP II é uma alterna-
tiva segura e eficaz para o tratamento de PCA, principalmente 
naqueles que apresentam limitações ao fechamento convencional.
DESCRITORES: Canal arterial. Próteses e implantes. Cardiopatias 
congênitas. Cateterismo cardíaco.
II prosthesis for PDA closure. The technical aspects, im-
mediate occlusion, and complication rates were evaluated.
METHODS
Study planning
This was an observational, prospective study with 
retrospective data collected from patients who under-
went PDA closure with the AVP II prosthesis at three 
reference centres for the percutaneous treatment of 
congenital heart disease.
Selection criteria
Patients with a patent ductus arteriosus with hemo-
dynamic effects, determined by left ventricular enlar-
gement on echocardiogram, were included. Patients 
weighing < 5 kg, patients with fixed pulmonary artery 
hypertension and patients with active infection at the 
time of the procedure were excluded.
Procedure
All patients and/or guardians signed an informed 
consent, and the patients were taken to the catheteri-
sation laboratory.
All patients underwent general anaesthesia and 
received prophylaxis for infectious endocarditis during 
the procedure; the antibiotic of choice was cefuroxime 
at a dose of 30  mg/kg to 50  mg/kg, followed by two 
additional doses. A femoral puncture was performed 
with the femoral sheaths positioned in the arterial and 
venous pathways. After the arterial puncture, heparin 
was administered at a dose of 50  U/kg to 100  U/kg, 
according to the institution’s routine protocol.
With a pigtail catheter positioned at the end of 
the aortic arch, angiographies were performed using 
the left profile view to determine the anatomy of the 
ductus arteriosus and to acquire measurements of the 
pulmonary extremity diameters, as well as the aortic 
ampulla and its length. In some cases, it was necessary 
to use other views (left oblique 100 degrees, with 10 
degrees of cranial angulation, or right oblique, 10 to 30 
degrees) for better visualisation of the entire trajectory 
of the channel. Aortic and pulmonary trunk pressures 
were measured in all patients.
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The implantation route was defined after choosing 
the prosthesis. In general, the route of choice was 
the antegrade venous route. The retrograde route 
was occa sionally used for a ductus < 3 mm. A 
therapeutic multipurpose or Judkins right coronary 
catheter with an internal diameter compatible with 
the passage of the device (defined by the table 
provided by the manufacturer) was used to deliver 
the prosthesis. New angiographies were performed 
before and after the prosthesis was released to 
evaluate the final position.
AVP II
The AVP II prosthesis, initially conceived for the 
occlusion of vessels (fistulas, collaterals),9 consists of 
a nitinol mesh with varying numbers of wires (144 to 
360) with different designs (one to three layers of wires) 
(Figure 1 A and B). It has three discs of equal diameter 
without the presence of tissue inside. A small flexible 
joint between the discs allows their articulation. The 
prosthetic diameter starts at 3 mm and continues up to 
22 mm, in 2 mm increments, beginning at 4 mm. The 
AVP II can be used with a guide catheter or extended 
introducers of varying sizes according to the manufac-
turer’s recommendations. The specifications for diameters, 
lengths, and compatibilities are shown in Table 1.
The prosthesis was selected after considering the 
minimum diameter of the channel, the diameter of 
the aortic ampulla, the total length of the channel, and the 
total length of the aortic ampulla. In general, the di-
ameter of the discs was at least two times greater than 
the minimum diameter of the channel, and was at most 
1  mm larger than the largest diameter of the aortic 
ampulla. The length of the device (which increases ac-
cording to the increase in disc diameter) did not exceed 
1 to 2  mm of the total length of the ductus arteriosus. 
Because this is a device with three retention discs, two 
discs were positioned on the aortic side, and the third 
disc was positioned on the pulmonary side of the ductus 
arteriosus (Figures 2 and 3).
Follow-up
Echocardiographic assessments, chest radiographs, 
and electrocardiographic evaluations were performed in 
all patients before hospital discharge, which occurred 
the day after the procedure. A new echocardiogram 
was performed six months after implantation.
TABLE 1  
Amplatzer® Vascular Plug II Models and Minimal Requirements
Amplatzer® Vascular Plug II Guide-catheter requirements
Diameter 
(mm)
Length 
(mm)
Minimum  
size  
(F)
Minimum  
internal diameter 
(inches)
Maximum  
internal diameter 
(inches)
Maximum  
length  
(cm)
3 6 5 0.056 0.067 100
4 6 5 0.056 0.098 100
6 6 5 0.056 0.098 100
8 7 5 0.056 0.106 100
10 7 6 0.070 0.106 100
12 9 6 0.070 0.106 100
14 10 8 0.086 0.106 100
16 12 8 0.086 0.106 100
18 14 9 0.098 0.106 100
20 16 9 0.098 0.106 100
22 18 9 0.098 0.106 100
Figure 1 – In A, Amplatzer® Vascular Plug II. In B, illustrative drawing 
showing the three discs and the device’s nitinol mesh.
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RESULTS
From March of 2011 to March of 2012, 40 patent 
ductus arteriosus closure procedures were performed 
in 40 patients using the AVP II device.
Of these patients, 27 were females (67.5%), and 
13 were males (32.5%). The median age and weight 
were 56.7 months (6 months to 654.7 months) and 
17.3  kg (5  kg to 93  kg), respectively. Ten patients 
weighed <  10  kg. The ductus arteriosus was classi-
fied, according to the Krichenko classification, as 
type A in 36 patients (90%), type E in three pa-
tients, and type C in one patient. Measurements of 
the ductus arteriosus at the time of catheterisation 
were 3.7  ±  1.5  mm at the pulmonary extremity, 
10 ± 4 mm in the aortic ampulla, and 8.8 ± 3.4 mm 
in length. The mean diameter of the device used was 
9.4 ± 3.6 mm. The systolic pulmonary artery pressure 
Figure 2 – Ductus arteriosus type A with a 2 mm diameter at the pulmonary extremity. A 4 mm Amplatzer® Vascular Plug II device was successfully 
employed. In A, initial aortography in the left view. In B, control aortography showing the device well positioned within the channel.
Figure 3 – Ductus arteriosus type A with a 2.8 mm diameter at the pulmonary extremity. An 8 mm Amplatzer® Vascular Plug II device was success-
fully employed. In A, initial aortography in left view. In B, control aortography showing the device well positioned within the ductus, with two discs 
inside the aortic ampulla and with no residual flow.
A B
A B
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was 30.4  ±  8.5  mmHg, and the aortic systolic pres-
sure was 86 ± 23 mmHg. The clinical, angiographic, 
and procedural data are shown in Table 2.
The antegrade implantation route was the preferred 
approach, with the exception of one procedure where 
the prosthesis was implanted using a retrograde route, 
which is the choice for patients with a small ductus 
because this route provides procedural dexterity. In this 
patient, who weighed 59  kg, the retrograde approach 
was used to treat a 1.5-mm ductus arteriosus with a 
3-mm prosthesis and a 5 F catheter (Figure 4).
The procedure was successfully completed in all 
but one of the patients. This patient weighed 7.4  kg, 
and the ductus was type C, measuring 5.5 mm at both 
ends (Figure 5). The pulmonary artery systolic pressure 
was 38  mmHg, and attempts were made with 8-mm 
and 10-mm AVP II prostheses. The first prosthesis was 
not released and was replaced. The second prosthesis 
led to embolisation of the right pulmonary artery after 
its release and was successfully recovered with the aid 
of a bioptome. The patient was subsequently referred 
for surgery, and complications were not recorded.
The prosthesis showed a slight disk protrusion to the 
aortic side in five patients, but none of them showed 
a significant pressure gradient as measured both in the 
catheterisation lab and on echocardiography.
In addition to the patient in whom embolisation 
occurred, device substitutions were required in three 
other patients. The first patient, who had a 3-mm 
ductus arteriosus at the pulmonary extremity, needed 
to exchange an 8-mm prosthesis for a 6-mm one; the 
final positioning was optimal (Figure 6). The second 
patient had a 5.7-mm PDA and a 16.8-mm aortic am-
pulla. A 12-mm prosthesis implant was placed and then 
replaced by an 18-mm implant. The first measurement 
of this ductus was 4 mm, most likely due to spasm 
during the injection of contrast, which resulted in an 
inaccurate assessment and undersizing of the prosthesis. 
Figure 4 – Small (1.5 mm) ductus arteriosus in which a 3-mm Amplatzer® Vascular Plug II device was successfully implanted via a retrograde route. 
In A, initial aortography in left view. In B, control aortography showing the device well positioned within the ductus and with no residual flow. 
TABLE 2 
Clinical, Angiographic, and Procedural Data
n = 40
Female gender, n (%) 27 (67.5)
Age, months 56.7 (6–654.7)
Weight, kg 17.3 (5–93)
Type A (Krichenko), n (%) 36 (90)
Pulmonary extremity, mm 3.7 ± 1.5
Aortic ampulla, mm 10 ± 4
Length (mm) 8.8 ± 3.4
Pulmonary artery systolic pressure, 
mmHg
30.4 ± 8.5
Aorta systolic pressure, mmHg 86 ± 23
Device employed, mm 9.4 ± 3.6
Antegrade implant route, n (%) 39 (97)
n = number of patients.
A B
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Figure 5 – Tubular ductus arteriosus type C, of high flow, with 5.5 mm diameter at both ends. Unsuccessful attempts were made to implant 8-mm 
and 10-mm Amplatzer® Vascular Plug II devices, with a resulting embolisation of the 10-mm prosthesis to the right pulmonary artery; the device 
was recovered with a bioptome. The control angiography after prosthesis recovery showed no signs of injury to the vascular wall. In A, initial 
aortography in left profile. In B, control aortography showing the 8-mm device poorly positioned within the ductus. In C, control aortography showing 
the 10-mm device well positioned within the ductus before its release. In D, the pulmonary trunk angiography showing the 10-mm device with 
protrusion toward the pulmonary artery after its release. In E, the embolised device in the pulmonary artery during recovery of the device, which 
was achieved using a bioptome.
D E
A B C
A B C
Figure 6 – PDA type E measuring 3 mm at the pulmonary extremity, in which an 8-mm Amplatzer® Vascular Plug II implant was placed and subse-
quently successfully replaced by a 6-mm one. In A, initial aortography in left view. In B, the angiography performed in the pulmonary trunk showing 
the 8-mm prosthesis with disc protrusion into the left pulmonary artery. In C, control aortography showing the 6-mm device well positioned within 
the ductus, with slight residual flow.
The third patient who required a device to be replaced 
had a 3.5-mm ductus arteriosus that was implanted 
in a 6.5  x  5  mm Flipper coil, which embolised and 
needed to be recovered. An 8-mm AVP II device was 
later implanted, which resulted in complete closure 
of the defect.
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All but one patient underwent post-procedure 
recovery in the catheterisation laboratory. The only 
patient whose recovery took place in the intensive care 
unit was a 9-month-old child who weighed 5 kg; after 
a period of six hours, the child was transferred to the 
paediatric ward.
The echocardiographic study performed 24 hours 
after the procedure showed complete closure of flow 
through the ductus arteriosus in all cases, except in 
two patients, who had minimal residual flow. There was 
no increase in flow velocity in the aorta or pulmonary 
artery. Those patients with minimal residual flow still 
had less than six months of follow-up when this article 
was written.
DISCUSSION
The present experience with the AVP II device 
showed good results, with high rates of PDA closure. 
Echocardiography performed 24 hours after the procedure 
revealed only intra-prosthesis residual flow with a low 
velocity. Due to the manufacturing characteristics of the 
device (with no tissue inside), immediate residual flow is 
usually observed and disappears in a short period of 
time (appro ximately 24 hours). The authors believe that 
total occlusion will be observed in all patients during 
the follow-up.
In one patient, the prosthesis was positioned via the 
arterial route without technical difficulties or vascular 
complications. This technique can be employed in simple 
cases to provide greater flexibility for the procedure. 
Since the AVP II is more flexible, it can pass through 
lower profile systems and can be used in lower-weight 
patients, such as the ten patients in this study.
Even when implanting devices that are smaller 
than the aortic ampulla (the mean aortic ampulla was 
10  mm and the prosthesis was 9.4  mm), there was 
slight distal disc protrusion to the aorta in five patients, 
especially in small children. Because there was no local 
gradient, the prostheses were released. It is believed 
that the angiographic appearance should improve as 
the patients grow. Device replacement was necessary 
in three patients at the beginning of the study. At that 
point in time, the authors were still looking for an ap-
propriate correlation between the size and anatomy of 
the PDA and the device being used. It is believed that, 
in addition to measurements of the aortic ampulla, the 
total length of both the ductus and the device should be 
taken into consideration so that there is no significant 
prolapse on the aortic side. Prolapse on the pulmonary 
side is unlikely because only one low profile disc is 
positioned on this side of the ductus.
There was only one unsuccessful case; the patient 
was small and had a large tubular ductus arteriosus. An 
attempt was made to implant a device approximately 30% 
larger than the diameter, treating the ductus as a vascular 
structure. Because the 8-mm prosthesis was not stable 
inside the ductus, a 10-mm implant was chosen. At first, 
this prosthesis showed satisfactory stability. However, after 
several minutes of observation, there was embolisation 
to the pulmonary artery. This episode exemplifies the 
difficulty of closing a tubular ductus that has great dis-
tensibility. The rescue with bioptome, introduced through 
a long 8 F sheath, presented no technical difficulties. 
Despite this unsuccessful case, Schwartz et al.9 reported 
occlusion of a tubular ductus arteriosus with the AVP 
II in a series of 14 patients, including ductus types C, 
D, and E according to the Krichenko classification. Ng 
et al.8 also reported the successful closure of a tubular 
ductus arteriosus in two patients, one of whom was 
a young infant who was 3 months old. Despite these 
previous unfavourable experiences, the authors believe 
that a ductus with these anatomic features and size in 
low-weight patients can be closed successfully with the 
use of a more compact prosthesis. In such scenarios, 
the Amplatzer® Duct Occluder II (ADO II AS, St. Jude 
Medical – St. Paul, USA) may be useful because it has 
a nitinol mesh, which makes it more dense, and it is 
distributed in a single layer. Unfortunately, this prosthesis 
is not yet available for clinical use in Brazil.
Further studies with larger numbers of patients, dif-
ferent anatomic variations, and long-term results must 
be performed to assess the precise role of the AVP II 
in the percutaneous closure of a PDA.
CONCLUSIONS
The AVP II prosthesis was safe and effective for 
closure of a PDA in patients in this small series. The 
prosthesis can be applied to a large or small arterial 
ductus, and it can be used in small children and adults 
with a wide aortic ampulla. The AVP II should be con-
sidered as another tool for the percutaneous treatment 
of patent ductus arteriosus in selected cases.
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